论文部分内容阅读
目的研究新基因HA117在肠腺癌细胞中的表达位置和分布情况,了解其与肠腺癌各临床病例特征的关系。方法应用免疫组化SP法,检测20例肠腺癌和10例结肠正常组织中HA117的表达。结果 HA117在肠腺癌中的表达阳性率为75%,在正常结肠组织中的表达阳性率为10%,其结果差异有统计学意义(P=0.001);结肠癌组织中的阳性表达率显著高于直肠癌组织和正常结肠组织(P=0.002)。在Ⅲ~Ⅳ期组织中的表达阳性率比Ⅰ~Ⅱ期高,有淋巴结转移组的表达阳性率比无淋巴结转移组高,低分化组的表达阳性率比中高分化组高,但其结果差异均无统计学意义(P>0.05)。结论 HA117在肠腺癌中有着广泛的分布,从而提示实体肿瘤对化疗药物的耐受性同样受HA117基因的影响。
Objective To study the expression location and distribution of HA117 in intestinal adenocarcinoma and to investigate its relationship with clinical features of enteric adenocarcinoma. Methods Immunohistochemical SP method was used to detect the expression of HA117 in 20 cases of intestinal adenocarcinoma and 10 cases of normal colon tissues. Results The positive expression rate of HA117 in intestinal adenocarcinoma was 75% and that in normal colon tissue was 10% (P = 0.001). The positive expression rate of HA117 in colon adenocarcinoma was significant Higher than those in rectal cancer tissues and normal colon tissues (P = 0.002). The positive expression rates in stage Ⅲ ~ Ⅳ were higher than those in stage Ⅰ ~ Ⅱ. The positive expression rate in lymph node metastasis group was higher than that in non-lymph node metastasis group, and the positive rate in poorly differentiated group was higher than that in moderately and poorly differentiated group, but the difference was significant No statistical significance (P> 0.05). Conclusion HA117 is widely distributed in intestinal adenocarcinoma, suggesting that the tolerance of solid tumors to chemotherapeutic drugs is also affected by HA117 gene.